Artificial heart panel review
This article was originally published in The Gray Sheet
Executive SummaryFDA's Circulatory System Devices Panel will feature cardiologists as well as cardiovascular surgeons when it convenes June 23 to review Abiomed's AbioCor, according to the firm. In an April 20 release, Abiomed notes it is pursuing a humanitarian device exemption for the product, supported by data from 15 patients, having filed with FDA in September 2004. Plans for a PMA will hinge on a timetable for AbioCor 2, currently in animal studies. The next-generation device could last longer, yet be 35% smaller than AbioCor, Abiomed notes...
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.